265 related articles for article (PubMed ID: 9702842)
1. AmBisome (liposomal amphotericin B): a comparative review.
Boswell GW; Buell D; Bekersky I
J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
[TBL] [Abstract][Full Text] [Related]
2. [Amphotericin B and its lipid formulations].
Ritter J
Mycoses; 2002; 45 Suppl 3():34-8. PubMed ID: 12690969
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.
Tollemar J; Klingspor L; Ringdén O
Clin Microbiol Infect; 2001; 7 Suppl 2():68-79. PubMed ID: 11525221
[TBL] [Abstract][Full Text] [Related]
4. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
5. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.
Adler-Moore J; Proffitt RT
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():21-30. PubMed ID: 11801577
[TBL] [Abstract][Full Text] [Related]
6. AmBisome targeting to fungal infections.
Adler-Moore J
Bone Marrow Transplant; 1994; 14 Suppl 5():S3-7. PubMed ID: 7703928
[TBL] [Abstract][Full Text] [Related]
7. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
8. [New lipid formulations of amphotericin B. Review of the literature].
Andrès E; Tiphine M; Letscher-Bru V; Herbrecht R
Rev Med Interne; 2001 Feb; 22(2):141-50. PubMed ID: 11234672
[TBL] [Abstract][Full Text] [Related]
9. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans.
Takemoto K; Yamamoto Y; Ueda Y
Microbiol Immunol; 2006; 50(8):579-86. PubMed ID: 16924142
[TBL] [Abstract][Full Text] [Related]
11. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
Heinemann V; Bosse D; Jehn U; Kähny B; Wachholz K; Debus A; Scholz P; Kolb HJ; Wilmanns W
Antimicrob Agents Chemother; 1997 Jun; 41(6):1275-80. PubMed ID: 9174183
[TBL] [Abstract][Full Text] [Related]
13. The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles.
Walker L; Sood P; Lenardon MD; Milne G; Olson J; Jensen G; Wolf J; Casadevall A; Adler-Moore J; Gow NAR
mBio; 2018 Feb; 9(1):. PubMed ID: 29437927
[TBL] [Abstract][Full Text] [Related]
14. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B.
Chen SC;
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():57-61. PubMed ID: 11801583
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B, AmBisome.
Hay RJ
J Infect; 1994 May; 28 Suppl 1():35-43. PubMed ID: 8077689
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
17. Fungal fatal attraction: a mechanistic review on targeting liposomal amphotericin B (AmBisome
Soo Hoo L
J Liposome Res; 2017 Sep; 27(3):180-185. PubMed ID: 28805117
[TBL] [Abstract][Full Text] [Related]
18. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
Viscoli C; Castagnola E
Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
[TBL] [Abstract][Full Text] [Related]
19. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome).
Adler-Moore JP; Chiang SM; Satorius A; Guerra D; McAndrews B; McManus EJ; Proffitt RT
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():63-71. PubMed ID: 1778893
[TBL] [Abstract][Full Text] [Related]
20. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology.
Clark AD; McKendrick S; Tansey PJ; Franklin IM; Chopra R
Br J Haematol; 1998 Oct; 103(1):198-204. PubMed ID: 9792308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
